Targeted treatment for chronic lymphocytic leukemia

Aisha Masood, Taimur Sher, Aneel Paulus, Kena C. Miller, Kasyapa S. Chitta, Asher A Chanan Khan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The treatment of chronic lymphocytic leukemia (CLL) has evolved over the last few decades. Recognition has increased of several key components of CLL biology currently manipulated for therapeutics. A milestone in the treatment of CLL was reached with the incorporation of immunotherapy with conventional chemotherapy. The fludarabine/ cyclophosphamide/rituximab combination has demonstrated survival advantage for the first time in the treatment of CLL. Several other biological compounds are being explored with the hope of improving responses, impacting survival, and ultimately curing CLL. Important agents being tested are targeted on CLL surface molecules and their ligands, signal transduction protein and oncogenes. This review provides a brief summary of the recent advances made in preclinical and clinical investigation of selected promising therapeutic agents, which lead the target-directed therapeutic approach.

Original languageEnglish (US)
Pages (from-to)169-183
Number of pages15
JournalOncoTargets and Therapy
Volume4
DOIs
StatePublished - 2011

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Therapeutics
Oncogene Proteins
Immunotherapy
Cyclophosphamide
Signal Transduction
Ligands
Drug Therapy

Keywords

  • Akt inhibitors
  • Bcl-2 inhibitors
  • CLL
  • Cyclin d kinase inhibitors
  • Heat shock protein inhibitors
  • Immunomodulatory drugs
  • Monoclonal antibodies

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Targeted treatment for chronic lymphocytic leukemia. / Masood, Aisha; Sher, Taimur; Paulus, Aneel; Miller, Kena C.; Chitta, Kasyapa S.; Chanan Khan, Asher A.

In: OncoTargets and Therapy, Vol. 4, 2011, p. 169-183.

Research output: Contribution to journalArticle

Masood, Aisha ; Sher, Taimur ; Paulus, Aneel ; Miller, Kena C. ; Chitta, Kasyapa S. ; Chanan Khan, Asher A. / Targeted treatment for chronic lymphocytic leukemia. In: OncoTargets and Therapy. 2011 ; Vol. 4. pp. 169-183.
@article{bd4916aa655b4feb93342feb068d5f38,
title = "Targeted treatment for chronic lymphocytic leukemia",
abstract = "The treatment of chronic lymphocytic leukemia (CLL) has evolved over the last few decades. Recognition has increased of several key components of CLL biology currently manipulated for therapeutics. A milestone in the treatment of CLL was reached with the incorporation of immunotherapy with conventional chemotherapy. The fludarabine/ cyclophosphamide/rituximab combination has demonstrated survival advantage for the first time in the treatment of CLL. Several other biological compounds are being explored with the hope of improving responses, impacting survival, and ultimately curing CLL. Important agents being tested are targeted on CLL surface molecules and their ligands, signal transduction protein and oncogenes. This review provides a brief summary of the recent advances made in preclinical and clinical investigation of selected promising therapeutic agents, which lead the target-directed therapeutic approach.",
keywords = "Akt inhibitors, Bcl-2 inhibitors, CLL, Cyclin d kinase inhibitors, Heat shock protein inhibitors, Immunomodulatory drugs, Monoclonal antibodies",
author = "Aisha Masood and Taimur Sher and Aneel Paulus and Miller, {Kena C.} and Chitta, {Kasyapa S.} and {Chanan Khan}, {Asher A}",
year = "2011",
doi = "10.2147/OTT.S7173",
language = "English (US)",
volume = "4",
pages = "169--183",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Targeted treatment for chronic lymphocytic leukemia

AU - Masood, Aisha

AU - Sher, Taimur

AU - Paulus, Aneel

AU - Miller, Kena C.

AU - Chitta, Kasyapa S.

AU - Chanan Khan, Asher A

PY - 2011

Y1 - 2011

N2 - The treatment of chronic lymphocytic leukemia (CLL) has evolved over the last few decades. Recognition has increased of several key components of CLL biology currently manipulated for therapeutics. A milestone in the treatment of CLL was reached with the incorporation of immunotherapy with conventional chemotherapy. The fludarabine/ cyclophosphamide/rituximab combination has demonstrated survival advantage for the first time in the treatment of CLL. Several other biological compounds are being explored with the hope of improving responses, impacting survival, and ultimately curing CLL. Important agents being tested are targeted on CLL surface molecules and their ligands, signal transduction protein and oncogenes. This review provides a brief summary of the recent advances made in preclinical and clinical investigation of selected promising therapeutic agents, which lead the target-directed therapeutic approach.

AB - The treatment of chronic lymphocytic leukemia (CLL) has evolved over the last few decades. Recognition has increased of several key components of CLL biology currently manipulated for therapeutics. A milestone in the treatment of CLL was reached with the incorporation of immunotherapy with conventional chemotherapy. The fludarabine/ cyclophosphamide/rituximab combination has demonstrated survival advantage for the first time in the treatment of CLL. Several other biological compounds are being explored with the hope of improving responses, impacting survival, and ultimately curing CLL. Important agents being tested are targeted on CLL surface molecules and their ligands, signal transduction protein and oncogenes. This review provides a brief summary of the recent advances made in preclinical and clinical investigation of selected promising therapeutic agents, which lead the target-directed therapeutic approach.

KW - Akt inhibitors

KW - Bcl-2 inhibitors

KW - CLL

KW - Cyclin d kinase inhibitors

KW - Heat shock protein inhibitors

KW - Immunomodulatory drugs

KW - Monoclonal antibodies

UR - http://www.scopus.com/inward/record.url?scp=84858807412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858807412&partnerID=8YFLogxK

U2 - 10.2147/OTT.S7173

DO - 10.2147/OTT.S7173

M3 - Article

VL - 4

SP - 169

EP - 183

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -